By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish, highlighting a significant risk: the increasing difficulty of replicating the efficacy of Chinese-origin assets in Western cohorts, which could lead to higher approval hurdles, narrower labels, and a need for more expensive and time-consuming trials. This risk extends to both small biotechs and large pharma companies that have built pipelines on these assets.
Risk: Difficulty in replicating Chinese-origin assets' efficacy in Western cohorts, leading to regulatory hurdles and increased trial costs.
Opportunity: None identified.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
It's normal for biotechs to buy intellectual property.
It can be risky for a company to underinvest in its own R&D capabilities.
For most of the past three decades, U.S.-listed biotech companies were fair proxies for homemade American science. But now, that assumption is fraying. By one estimate from investment bank Jefferies, roughly a third of the industry's licensing spending in 2025 went toward drugs and candidates that originated in China, where lower costs and faster regulators have turned its labs into a firehose of ready-to-license molecules and programs.
In antibody-drug conjugates (ADCs) -- an increasingly sophisticated class of targeted therapies -- Chinese biotechs now supply close to 90% of global licensing activity. The question is, when you buy a U.S. biotech stock whose most promising programs were invented elsewhere, by another company, what are you actually holding?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
In some cases, the answer to that question might contain an unpleasant surprise for investors, which is why this trend of importing innovation is also an emerging risk worth understanding.
Summit Therapeutics (NASDAQ: SMMT) is a biotech with an investment thesis that's almost entirely dependent on the success of ivonescimab, an antibody therapy for various cancers that it licensed from China's Akeso in 2022, paying $500 million up front and low-double-digit royalties on sales. Summit didn't discover the molecule; it bought the right to sell it in the U.S., Europe, and Japan.
In May 2025, according to the first peek, investors were given data from ivonescimab's global phase 3 trial for patients with previously treated, EGFR-mutated non-small cell lung cancer (NSCLC). Treatment with ivonescimab plus chemotherapy led to an impressive 48% gain in progression-free survival (PFS). But the data for overall survival (how long patients lived) did not pass the threshold for statistical significance.
After the full trial data were presented later in the year, there was another, even larger issue: The cohorts of patients from Western countries saw only a 33% reduction in the risk of progression or death, versus a 45% reduction in Chinese patients, with the Western group's benefit not being statistically significant. And that's precisely the kind of discrepancy that regulators at the U.S. Food and Drug Administration (FDA) are likely to take issue with before they decide whether to approve ivonescimab, slated for mid-November of this year.
Similarly, shortly before that readout, an FDA panel ruled that a largely Asian data set supporting another cancer drug was inapplicable to U.S. patients, a precedent that now shadows every China-heavy trial and, by extension, nearly all trials of candidates licensed from China. Summit filed with the FDA for a narrower second-line use indication in early 2026, giving up some of its grander ambitions for ivonescimab.
Investors who bet that Akeso's data would be easy for Summit to replicate, leading to a low-risk, easy approval process for ivonescimab in the U.S., have not fared well. The biotech's stock is down 35% in the last 12 months. This emerging risk contributed to that decline, alongside a broadly weak biotech market and ivonescimab's survival shortfall.
This risk applies to major pharma companies and stocks as well.
For instance, Merck (NYSE: MRK) has leaned hard on Chinese innovation, including with a seven-drug deal with Kelun-Biotech worth $175 million up front and up to $9.3 billion in milestones. It hasn't experienced any of the same problems as Summit did, at least not yet.
Still, this problem is not a passing phase; China's latest five-year plan, approved in 2026, names biotechnology a "frontier" priority. The supply of licensable assets will only grow from here. Many of the U.S. biopharmas that rely on those assets will satisfy the FDA that their candidates are safe and effective. Others will hit the same wall Summit did: Global populations and the way clinical trial sites operate from one country to the next vary enough that some mismatches are inevitable.
The best way for investors to protect themselves is to ask where a company's value comes from before buying any shares. A business that discovers, develops, and manufactures its own drugs deserves a richer valuation than a stack of licensed-in bets because the licensee carries extra risks related to royalties going to the originator and whether foreign data clears the FDA.
That doesn't make Summit or its peers uninvestable, but it does mean that many clinical-stage stocks will look cheap because someone else has built most of their underlying value, which can be problematic.
Before you buy stock in Summit Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Summit Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $463,900! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,294,401!
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 31, 2026. *
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Jefferies Financial Group, Merck, and Summit Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Summit's heavy dependence on Akeso-licensed ivonescimab creates elevated FDA rejection risk that the market has not fully priced in."
The article flags a genuine structural risk: Summit's ivonescimab data showed a 33% PFS benefit in Western patients versus 45% in Chinese patients, with the former missing statistical significance. This precedent, plus the FDA's recent rejection of another Asian-heavy dataset, suggests licensors of Chinese assets face higher approval hurdles and narrower labels than originators. The trend is accelerating under China's 2026 biotech plan, yet most U.S. biotechs price these programs as if replication risk is minimal. Investors should apply steeper discounts to valuation multiples for companies whose pipelines are majority in-licensed rather than internally discovered.
The FDA has historically accepted multi-ethnic data with proper stratification, and Summit could still secure approval in a narrower indication by running supplemental Western trials that close the gap.
"Summit's problem is trial design failure in Western cohorts, not that Chinese innovation is categorically unworkable in U.S. markets."
The article conflates two distinct risks that deserve separation. Summit's ivonescimab failure stems from a real regulatory problem: Western trial cohorts underperformed Asian ones, triggering FDA skepticism of geographic heterogeneity. That's a legitimate approval risk. But the broader claim—that China-sourced biotech is inherently risky—overstates the case. Merck's $9.3B Kelun deal hasn't stumbled. The real issue isn't origin; it's trial design. If Chinese sponsors run adequately powered Western cohorts from day one, geographic mismatch evaporates. The article treats this as structural when it's often methodological. Valuation discount for licensing risk is rational, but conflating 'licensed-in' with 'doomed' ignores that many approved drugs were in-licensed.
Chinese biotech licensing could actually *improve* FDA approval odds if it forces sponsors to run larger, more rigorous Western trials earlier—raising trial costs but reducing late-stage surprises. The article assumes Western data gaps are inevitable; they're not.
"The regulatory premium on non-U.S. clinical data is rising, forcing a valuation compression for biotech firms that rely on licensing rather than internal discovery."
The article correctly identifies a structural shift: the 'China-to-West' licensing arbitrage is facing a regulatory reckoning. The FDA's growing skepticism toward non-U.S. clinical data—specifically regarding patient heterogeneity in oncology trials—creates a massive valuation trap for 'empty' biotech shells that lack internal R&D. While investors previously priced these assets as de-risked 'plug-and-play' therapies, the reality is that replicating Chinese efficacy in Western cohorts is statistically fraught. Summit Therapeutics (SMMT) is the canary in the coal mine, but the risk extends to Big Pharma players like Merck (MRK) that have built massive pipelines on the assumption of regulatory equivalence. We are seeing a fundamental re-rating of 'licensed' innovation versus 'native' R&D.
The FDA's scrutiny may simply lead to better trial design and global harmonization, potentially creating a 'buy the dip' opportunity for high-quality assets that were unfairly discounted due to their origin.
"Cross-border licensing risks can be managed with bridging data and co-development, but the market is mispricing the probability of prolonged regulatory headwinds and royalty drag for licensed-in assets like Summit, creating a potential near-to-medium-term downside."
Opening takeaway: The piece flags a real risk—China-origin assets complicating FDA approvals and shrinking the value of licensed-in bets—but the risk isn't purely regulatory. While bridging data will become more routine, it’s not automatic or universally accepted; a material share of value in licensed programs still rests on control of development timelines, co‑development terms, and the ability to harmonize foreign data with US pivotal trials. Expect higher upfront royalties and stricter post‑approval commitments, which could compress margins for licensees. Summit’s 12‑month drop likely reflects idiosyncrasies, not a universal collapse of licensing models. Deeper dislocation may emerge in mispriced, data-ready licenses.
The strongest counter-argument is that regulators have routinely allowed bridging data from foreign trials when backed by robust US pivotal programs; thus, the 'imported innovation' risk may be overstated and Summit's drop could reflect company-specific issues rather than a secular headwind.
"Ethnic response differences create replication costs that trial redesign alone cannot eliminate for China-origin assets."
Claude separates trial design from origin risk too cleanly. Summit's PFS gap (33% Western vs 45% Chinese) points to persistent ethnic differences in oncology response that extra Western cohorts won't erase; they only raise costs and delay timelines. This directly undercuts the claim that Merck's Kelun assets face only methodological issues. The same replication friction applies, compressing value for any licensee relying on Asian-heavy data without built-in bridging studies.
"Geographic efficacy gaps are real but addressable through trial design; Summit's failure reflects poor sponsor planning, not inherent licensing risk."
Grok conflates pharmacological heterogeneity with trial design failure. A 33% vs 45% PFS gap could reflect patient selection (disease stage, prior treatment burden), not immutable ethnic biology. Merck's Kelun deal hasn't stumbled precisely because Merck runs integrated global trials from inception—not because ethnic differences don't exist, but because they're *designed for* upfront. Summit's error wasn't licensing; it was treating Asian efficacy as portable without prospective Western validation. That's a sponsor execution failure, not a licensing model collapse.
"The requirement for rigorous Western trials to validate Chinese assets destroys the cost-arbitrage advantage that justified the licensing model's premium valuation."
Claude, your focus on 'sponsor execution' misses the macro-financial reality: the cost of that execution is ballooning. If 'proper' Western trials are now mandatory for Chinese-origin assets, the arbitrage that fueled the licensing boom is dead. You’re describing a model that requires massive, expensive, de-novo Western trials, which strips away the primary value proposition of in-licensing: speed and cost-efficiency. We are moving from a 'plug-and-play' model to a 're-do-the-work' model, which necessitates a permanent valuation haircut.
"Hybrid licensing models will persist and arbitrage isn’t dead; western-ready trials can unlock value but at higher costs and milestones."
Gemini, you tilt toward a permanent end to China-to-West licensing arbitrage, but that misses the nuance that many deals will evolve into hybrid models: upfront Western pivotal work plus staged licensing milestones, or selective licensing for assets with robust Western datasets. The drag is real—costs and timelines rise—but not abolition. Some assets will still monetize via licensing, just at a higher hurdle and with tighter post-approval obligations.
The panel consensus is bearish, highlighting a significant risk: the increasing difficulty of replicating the efficacy of Chinese-origin assets in Western cohorts, which could lead to higher approval hurdles, narrower labels, and a need for more expensive and time-consuming trials. This risk extends to both small biotechs and large pharma companies that have built pipelines on these assets.
None identified.
Difficulty in replicating Chinese-origin assets' efficacy in Western cohorts, leading to regulatory hurdles and increased trial costs.